Analyst Reco. Akeso, Inc.

Equities

9926

KYG0146B1032

Delayed Hong Kong S.E. Other stock markets 07:48:11 03/05/2024 am IST			5-day change	1st Jan Change
48.9 ^HKD	+0.20%		+4.05%	+5.28%

24/04	Akeso’s Supplemental New Drug Application for Cervical Cancer Drug Accepted by Chinese Regulator	MT
24/04	National Medical Products Administration Accepted the Supplemental New Drug Application by Akeso, Inc. for (Cadonilimab, Pd-1/Ctla-4) as First-Line Treatment for Cervical Cancer	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Nomura Adjusts Akeso’s Price Target to HK$52.80 From HK$48.84, Keeps at Buy	23/02	MT
Nomura Adjusts Akeso's Price Target to HK$48.84 From HK$50.14, Keeps at Buy	26/23/26	MT
Nomura Adjusts Akeso's Price Target to HK$50.14 From HK$46.04, Keeps at Buy	23/23/23	MT
Nomura Adjusts Akeso's Price Target to HK$46.04 From HK$31.54, Keeps at Buy	07/22/07	MT
Nomura Adjusts Akeso's Price Target to HK$31.54 From HK$35.81, Keeps at Buy	24/22/24	MT
UBS Adjusts Akeso’s Price Target to HK$26.68 From HK$29.60, Keeps at Buy	08/22/08	MT
UBS Adjusts Akeso’s Price Target to HK$29.60 From HK$32.40, Keeps at Buy	05/22/05	MT
Nomura Adjusts Akeso's Price Target to HK$35.81 From HK$53.66, Keeps at Buy	01/22/01	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

+39.41% on our US portfolio vs. 25.67% on the S&P 500 net Total Return

Replicate our performance

fermer